Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 58 of the 62 references it cites were found in a registry or an index.

Stromal fibroblasts mediate anti-PD-1 resistance via MMP-9 and dictate TGFβ inhibitor sequencing in melanoma

Open access

Published version of a preprint

Abstract

Although anti–PD-1 therapy has improved clinical outcomes for select patients with advanced cancer, many patients exhibit either primary or adaptive resistance to checkpoint inhibitor immunotherapy. The role of the tumor stroma in the development of these mechanisms of resistance to checkpoint inhibitors remains unclear. We demonstrated that pharmacologic inhibition of the TGFβ signaling pathway synergistically enhanced the efficacy of anti–CTLA-4 immunotherapy but failed to augment anti–PD-1/PD-L1 responses in an autochthonous model of BRAFV600E melanoma. Additional mechanistic studies revealed that TGFβ pathway inhibition promoted the proliferative expansion of stromal fibroblasts, thereby facilitating MMP-9–dependent cleavage of PD-L1 surface expression, leading to anti–PD-1 resistance in this model. Further work demonstrated that melanomas escaping anti–PD-1 therapy exhibited a mesenchymal phenotype associated with enhanced TGFβ signaling activity. Delayed TGFβ inhibitor therapy, following anti–PD-1 escape, better served to control further disease progression and was superior to a continuous combination of anti–PD-1 and TGFβ inhibition. This work illustrates that formulating immunotherapy combination regimens to enhance the efficacy of checkpoint blockade requires an in-depth understanding of the impact of these agents on the tumor microenvironment. These data indicated that stromal fibroblast MMP-9 may desensitize tumors to anti–PD-1 and suggests that TGFβ inhibition may generate greater immunologic efficacy when administered following the development of acquired anti–PD-1 resistance. See related Spotlight on p. 1444

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/2326-6066.cir-18-0086

Cites

58 of 58 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 62 references

Research works printed but not linked: 1

  1. Hanks, 2013, Type III TGF-beta receptor downregulation generates an immunotolerant tumor microenvironment, J Clin Invest, 123, 3925, 10.1172/JCI65745 · DOI

Cited by

See all 123

Metadata

Authors
Zhao, F., Evans, K., Xiao, C., DeVito, N., Theivanthiran, B., Holtzhausen, A., Siska, P. J., Blobe, G. C., & Hanks, B. A.
Affiliations
  • Duke University (US)
  • University of North Carolina at Chapel Hill (US)
  • University Hospital Regensburg (DE)
Corresponding author
Hanks, Brent A.
Venue
Cancer Immunology Research
Published
2018-12-01
Volume
6
Issue
12
Pages
1459-1471
ISSN
  • 2326-6066 (ISSN-L)
  • 2326-6074
OpenAlex
W2890611687
Cited by
117
References
62
Citations by year
2026: 6 · 2025: 18 · 2024: 8 · 2023: 7 · 2022: 22 · 2021: 17 · 2020: 23 · 2019: 15 · 2018: 1
FWCI
5.25
Type
journal article
Language
en
Open access
Locations
  • Cancer Immunology Research (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
  • University of Regensburg Publication Server (University of Regensburg) (submittedVersion)
Funders
  • HHS | National Institutes of Health (NIH) (1K08CA191063-01A1)
  • Melanoma Research Alliance (MRA) (Young Investigator Award)
  • Duke University School of Medicine (Duke Health Scholars Award)
  • MedPacto, Inc. (Pre-clinical Research Award)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
Keywords
anti-PD-1 resistance, tumor stromal fibroblasts, TGF-beta inhibition, MMP-9, melanoma, BRAF V600E mutation, tumor microenvironment, mesenchymal phenotype, immunotherapy resistance, treatment sequencing
MeSH terms
Animals, Female, Fibroblasts, Immunotherapy, Male, Melanoma, Mice, Inbred BALB C, Mice, Inbred C57BL, Mice, Transgenic, Pyrazoles, Quinolines, Transforming Growth Factor beta, Drug Resistance, Neoplasm, Matrix Metalloproteinase 9, Xenograft Model Antitumor Assays, Proto-Oncogene Proteins B-raf, Tumor Microenvironment, B7-H1 Antigen, CTLA-4 Antigen

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Stromal fibroblasts mediate anti-PD-1 resistance via MMP-9 and dictate TGFβ inhibitor sequencing in melanoma. https://app.cochat.ai/papers/10.1158/2326-6066.cir-18-0086
The paper
Zhao, F., Evans, K., Xiao, C., DeVito, N., Theivanthiran, B., Holtzhausen, A., Siska, P. J., Blobe, G. C., & Hanks, B. A. (2018). Stromal fibroblasts mediate anti-PD-1 resistance via MMP-9 and dictate TGFβ inhibitor sequencing in melanoma. Cancer Immunology Research. https://doi.org/10.1158/2326-6066.cir-18-0086

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.